Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/17/2024 | $19.00 | Buy | Jefferies |
| 4/4/2024 | Overweight | Cantor Fitzgerald | |
| 2/12/2024 | $18.00 | Overweight | Piper Sandler |
| 12/8/2023 | $16.00 | Buy | B. Riley Securities |
| 10/20/2022 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 9/20/2021 | $25.00 | Outperform | SVB Leerink |
| 9/7/2021 | $12.00 | Outperform | Wedbush |
| 9/7/2021 | $20.00 | Outperform | Wedbush |
Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Price Target of $19.
Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.
In the preceding three months, 6 analysts have released ratings for Tango Therapeutics (NASDAQ:TNGX), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.5, a high estimate of $17.00, and a low estimate of $11.00. A 17.33% drop is evident in the current average co
– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 – – Strong cash position of $293 million as of September 30, 2024, with cash runway into 3Q 2026 to prioritize resourcing of TNG462 and TNG456 clinical trials – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoveri
– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development – – Multiple TNG462 combination studies planned in 1H 2025 – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – TNG456, a next-generation brain penetrant MTA-cooperative PRMT5 inhibitor with enhanced potency and MTAP-deleted-selectivity, entering phase 1/2 clinical trial 1H 2025 to be evaluated both as a monotherapy and in combination with CDK4/6 inhibitor abemaciclib – – TNG908 en
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in September. 2024 Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 12:45 PM ET Location: Boston, MA 2024 Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 9:10 AM ET Location: New York, NY A live webcast of the presentations will be available under the "Events & Presentations" tab on the "In
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)
8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
144 - Tango Therapeutics, Inc. (0001819133) (Subject)
Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00
Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight
Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)